Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML

Blood (2024) 144 (Supplement 1): 1485.

https://doi.org/10.1182/blood-2024-203422

Published: 2024

Journal Articles

A Specific Coagulation Factor X Activator for on-Demand Treatment in Hemophilia with Inhibitors

Wei Liu, Hu Zhou, Ruibin Huang, Xin Du, ZePing Zhou, Changcheng Zheng, Shifeng Lou, Xinyue Dai, Renchi Yang, Lei Zhang

Blood (2024) 144 (Supplement 1): 1213.

https://doi.org/10.1182/blood-2024-199149

Published: 2024

Journal Articles

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Blood (2024) 144 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2024-204447

Published: 2024

Journal Articles

7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2885.

https://doi.org/10.1182/blood-2024-198844

Published: 2024

Journal Articles

Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia

Lei Ju, Xingli Zhao, Xiaohui Suo, ZePing Zhou, Yanliang Bai, Yunya Luo, Sifeng Gao, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Yaxian Tan, Guanchen Bai, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2024) 144 (Supplement 1): 1505.

https://doi.org/10.1182/blood-2024-202971

Published: 2024

Journal Articles

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia

ZePing Zhou, Yaxian Tan, Xingli Zhao, Xiaohui Suo, Guanchen Bai, Yanliang Bai, Yunya Luo, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2024) 144 (Supplement 1): 4279.

https://doi.org/10.1182/blood-2024-202430

Published: 2024

Journal Articles

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Blood (2024) 144 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2024-202790

Published: 2024

Journal Articles

Optimized Recombinant Human Thrombopoietin(rhTPO) Regimen Versus Eltrombopag for Pre-Treated Patients with Primary Immune Thrombocytopenia: Interim Results from a Prospective, Multicenter, Randomized Trial (TE-ITP study)

Yunfei Chen, Ting Sun, Da Gao, Wei Wang, ZePing Zhou, Guangxun Gao, Yi Wang, Hu Zhou, Yanping Song, Yinghui Lai, Zhenyu Yan, Jinsong Yan, Jie Bai, Lei Zhang

Blood (2024) 144 (Supplement 1): 3937.

https://doi.org/10.1182/blood-2024-202716

Published: 2024

Journal Articles

Efficacy and Safety of Beceltinib Capsules in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Open-Label, Phase 1/2 Study

Hu Zhou, Xuewen Song, Zengmei Sheng, Feng Zhang, Guocai Wu, Lidong Zhao, ZePing Zhou, Lihong Shou, Lili Chen, Xiaotao Wang, Jian Huang, Rong Fu, Dan Chen, Ruibin Huang, Zongjiu Jiao, Jian Lu, Yajun Ruan, Yu Jiao

Blood (2024) 144 (Supplement 1): 5406.

https://doi.org/10.1182/blood-2024-200074

Published: 2024

Journal Articles

Efficacy and Safety of an Engineered, Liver-Tropic Adeno-Associated Virus Vector Expressing Factor IX Padua Administered with Prophylactic Glucocorticoids in Patients with Hemophilia B: A Multi-Center, Single-Arm, Phase 3 Trial

Feng Xue, Mankai Ju, Tienan Zhu, ZePing Zhou, Jing Sun, Linhua Yang, Zhenyu Yan, Hu Zhou, Xin Du, Changcheng Zheng, Xia Wu, Xiao Xiao, Renchi Yang, Lei Zhang

Blood (2024) 144 (Supplement 1): 3582.

https://doi.org/10.1182/blood-2024-204715

Published: 2024

Journal Articles

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) VS Venetoclax Combined with Azacitidine in Elderly Patients with Acute Myeloid Leukemia：a Phase III, Prospective, Multicenter, Randomized Controlled Trial

Blood (2024) 144 (Supplement 1): 6035.

https://doi.org/10.1182/blood-2024-202495

Published: 2024

Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Blood (2024) 144 (18): 1951–1961.

https://doi.org/10.1182/blood.2024024761

Published: 2024

Includes: Supplemental data

Journal Articles

Emicizumab Prophylaxis for the Treatment of Chinese Hemophilia A Patients in the Real World: A Multi-Center Retrospective Analysis

Blood (2023) 142 (Supplement 1): 2624.

https://doi.org/10.1182/blood-2023-174698

Published: 2023

Journal Articles

Short-Term Efficacy of Combination Therapy with Recombinant Human Thrombopoietin (rh-TPO) and Thrombopoietin Receptor Agonists (TPO-Ra) in Patients with Severe Immune Thrombocytopenia

Renxia Li, Wen Yang, Yaxian Tan, Renchi Yang, ZePing Zhou

Blood (2023) 142 (Supplement 1): 5445.

https://doi.org/10.1182/blood-2023-188288

Published: 2023

Journal Articles

Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)

Blood (2023) 142 (Supplement 1): 1814.

https://doi.org/10.1182/blood-2023-179043

Published: 2023

Journal Articles

The Efficacy and Safety of Modified Melphalan and Busulfan-Based Conditioning Regimen for Allogeneic-HSCT in Refractory/Relapsed or Persistent MRD Positive AML Patients

Shulian Chen, Xiaoyu Zhang, Weihua Zhai, Yi He, Sizhou Feng, Mingzhe Han, Ting Niu, Yajing Xu, Guangxun Gao, Shengjin Fan, Zeping Zhou, Fang Zhou, Xi Rui, Li Liu, Wei Yang, Qifa Liu, Xi Zhang, Erlie Jiang

Blood (2022) 140 (Supplement 1): 10467–10468.

https://doi.org/10.1182/blood-2022-165140

Published: 2022

Journal Articles

Aberrant Expression of a Proliferation-Inducing Ligand Underlies Autoimmune Mechanisms in Immune Thrombocytopenia

Yunfeng Hao, Renchi Yang, MD, Zeping Zhou

Blood (2018) 132 (Supplement 1): 3763.

https://doi.org/10.1182/blood-2018-99-111743

Published: 2018

Journal Articles

Increased Prevalence of Activated CD83+CD4+ T Cells with Immune Thrombocytopenia

Yunlong Wang, Jr., MD, Shixuan Wang, Jr., MD, Zeping Zhou, Sr., MD, Huiyuan Li, Jr., Renchi Yang, Sr., MD

Blood (2017) 130 (Supplement 1): 4850.

https://doi.org/10.1182/blood.V130.Suppl_1.4850.4850

Published: 2017

Journal Articles

Effects of RNA Interference on CD70 in Dendritic Cells of Patients with Immune Thrombocytopenia

Zeping Zhou, Sr., MD, Yunlong Wang, Jr., MD, Renchi Yang, MD PhD, Huiyuan Li, PhD

Blood (2016) 128 (22): 1373.

https://doi.org/10.1182/blood.V128.22.1373.1373

Published: 2016

Journal Articles

Lower Dosages of Intravenous Immunoglobulin (IVIg) in Treating Immune Thrombocytopenia with Long-Term Follow-up of Three Years

Zeping Zhou, Sr., MDPhD, Zhuoqing Qiao, MD, Huiyuan Li, PhD, Xian Zhang, PhD, Feng Xue, MDPhD, Renchi Yang, MDPhD

Blood (2015) 126 (23): 3480.

https://doi.org/10.1182/blood.V126.23.3480.3480

Published: 2015

NARROW

Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML

A Specific Coagulation Factor X Activator for on-Demand Treatment in Hemophilia with Inhibitors

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia

Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Optimized Recombinant Human Thrombopoietin(rhTPO) Regimen Versus Eltrombopag for Pre-Treated Patients with Primary Immune Thrombocytopenia: Interim Results from a Prospective, Multicenter, Randomized Trial (TE-ITP study)

Efficacy and Safety of Beceltinib Capsules in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Open-Label, Phase 1/2 Study

Efficacy and Safety of an Engineered, Liver-Tropic Adeno-Associated Virus Vector Expressing Factor IX Padua Administered with Prophylactic Glucocorticoids in Patients with Hemophilia B: A Multi-Center, Single-Arm, Phase 3 Trial

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) VS Venetoclax Combined with Azacitidine in Elderly Patients with Acute Myeloid Leukemia：a Phase III, Prospective, Multicenter, Randomized Controlled Trial

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Emicizumab Prophylaxis for the Treatment of Chinese Hemophilia A Patients in the Real World: A Multi-Center Retrospective Analysis

Short-Term Efficacy of Combination Therapy with Recombinant Human Thrombopoietin (rh-TPO) and Thrombopoietin Receptor Agonists (TPO-Ra) in Patients with Severe Immune Thrombocytopenia

Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)

The Efficacy and Safety of Modified Melphalan and Busulfan-Based Conditioning Regimen for Allogeneic-HSCT in Refractory/Relapsed or Persistent MRD Positive AML Patients

Aberrant Expression of a Proliferation-Inducing Ligand Underlies Autoimmune Mechanisms in Immune Thrombocytopenia

Increased Prevalence of Activated CD83+CD4+ T Cells with Immune Thrombocytopenia

Effects of RNA Interference on CD70 in Dendritic Cells of Patients with Immune Thrombocytopenia

Lower Dosages of Intravenous Immunoglobulin (IVIg) in Treating Immune Thrombocytopenia with Long-Term Follow-up of Three Years

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only